FocalSeal shows promise for drug delivery:
This article was originally published in Clinica
Executive Summary
Focal has reported promising results from a pre-clinical study to evaluate the use of its FocalSeal polymer technology for the local delivery of chemotherapeutic drugs. Researchers formulated the company's water-based hydrogel with the drug, camptothecin, to coat breast cancer tumours in mice. Over 60% of the mice exhibited complete regression over three months versus a control group. The delivery method represents an advance compared to other local delivery approaches, said the Lexington, Massachusetts company. FocalSeal is currently marketed as a surgical sealant.